LIM2

Summary

LIM2 (lens intrinsic membrane protein 2, HGNC:6610) is a protein-coding gene on chromosome 19q13.41, encoding Lens fiber membrane intrinsic protein (P55344). Present in the thicker 16-17 nm junctions of mammalian lens fiber cells, where it may contribute to cell junctional organization.

This gene encodes an eye lens-specific protein found at the junctions of lens fiber cells, where it may contribute to cell junctional organization. It acts as a receptor for calmodulin, and may play an important role in both lens development and cataractogenesis. Mutations in this gene have been associated with cataract formation. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 3982 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cataract 19 multiple types (Definitive, GenCC) — +1 more curated relationship
• GWAS associations: 1
• Clinical variants (ClinVar): 113 total — 2 pathogenic
• Phenotypes (HPO): 4
• MANE Select transcript: NM_001161748

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6610
Approved symbol	LIM2
Name	lens intrinsic membrane protein 2
Location	19q13.41
Locus type	gene with protein product
Status	Approved
Aliases	MP19, MP17
Ensembl gene	ENSG00000105370
Ensembl biotype	protein_coding
OMIM	154045
Entrez	3982

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000221973, ENST00000596399, ENST00000853599

RefSeq mRNA: 2 — MANE Select: NM_001161748 NM_001161748, NM_030657

CCDS: CCDS12831, CCDS59415

Canonical transcript exons

ENST00000596399 — 5 exons

Exon	Start	End
ENSE00000722291	51382418	51382567
ENSE00001125101	51380505	51380639
ENSE00003049758	51387269	51387449
ENSE00003183783	51387919	51387974
ENSE00003901368	51379909	51380262

Expression profiles

Bgee: expression breadth broad, 26 present calls, max score 89.48.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3719 / max 47.9186, expressed in 84 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182402	0.3719	84

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.48	gold quality
lens of camera-type eye	UBERON:0000965	87.09	gold quality
granulocyte	CL:0000094	77.02	gold quality
type B pancreatic cell	CL:0000169	68.89	gold quality
triceps brachii	UBERON:0001509	66.68	gold quality
gluteal muscle	UBERON:0002000	66.50	gold quality
pigmented layer of retina	UBERON:0001782	65.98	gold quality
olfactory bulb	UBERON:0002264	64.84	gold quality
pancreatic ductal cell	CL:0002079	64.70	silver quality
diaphragm	UBERON:0001103	64.12	gold quality
secondary oocyte	CL:0000655	61.79	gold quality
tibialis anterior	UBERON:0001385	61.63	silver quality
heart right ventricle	UBERON:0002080	60.92	gold quality
ileal mucosa	UBERON:0000331	60.08	silver quality
deltoid	UBERON:0001476	58.51	gold quality
blood	UBERON:0000178	55.39	gold quality
myocardium	UBERON:0002349	55.20	gold quality
epithelial cell of pancreas	CL:0000083	54.87	gold quality
quadriceps femoris	UBERON:0001377	54.82	gold quality
vastus lateralis	UBERON:0001379	53.74	gold quality
nasal cavity epithelium	UBERON:0005384	53.69	gold quality
decidua	UBERON:0002450	52.81	gold quality
biceps brachii	UBERON:0001507	52.46	gold quality
cartilage tissue	UBERON:0002418	52.30	gold quality
left ventricle myocardium	UBERON:0006566	51.85	gold quality
Brodmann (1909) area 46	UBERON:0006483	51.27	gold quality
bone marrow	UBERON:0002371	50.21	gold quality
epithelium of bronchus	UBERON:0002031	50.19	gold quality
bone marrow cell	CL:0002092	50.15	gold quality
bronchus	UBERON:0002185	49.81	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6505	yes	671.84
E-ANND-3	no	1.47

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): LHX2

miRNA regulators (miRDB)

13 targeting LIM2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-5691	98.23	67.02	1335
HSA-MIR-6805-3P	98.23	67.02	1334
HSA-MIR-660-3P	98.14	66.04	1434
HSA-MIR-1225-3P	97.29	64.60	876
HSA-MIR-874-5P	96.93	63.92	1014
HSA-MIR-3914	94.91	65.77	643

Literature-anchored findings (GeneRIF, showing 9)

• A missense mutation in the LIM2 gene is associated with autosomal recessive presenile cataract in an inbred Iraqi Jewish family (PMID:11917274)
• Since the LIM2 gene promoter does not contain a classic TATA box, the Hsu element may serve as the site for binding the RNA polymerase complex. (PMID:15968979)
• This study shows the involvement of LIM2 in human congenital cataract. (PMID:18596884)
• The genetic mutation in GJA3, GJA8, and LIM2 may slightly contribute to the development of age-related cataracts. (PMID:21386927)
• we report the absence of mutations in all studied genes in four families with phenotypes associating cataract, mental retardation and microcephaly. (PMID:22103961)
• A novel missense mutation in LIM2 is responsible for autosomal recessive congenital cataracts. (PMID:27814360)
• A novel missense mutation in LIM2 causing isolated autosomal dominant congenital cataract. (PMID:32202185)
• A recurrent variant in LIM2 causes an isolated congenital sutural/lamellar cataract in a Japanese family. (PMID:35736209)
• Novel and known variants in GJA3 and LIM2 in congenital cataract families from North India. (PMID:38178039)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	lim2.4	ENSDARG00000015445
danio_rerio	lim2.5	ENSDARG00000041295
mus_musculus	Lim2	ENSMUSG00000118560
rattus_norvegicus	Lim2	ENSRNOG00000017681

Paralogs (10): NKG7 (ENSG00000105374), PMP22 (ENSG00000109099), GSG1 (ENSG00000111305), EMP1 (ENSG00000134531), EMP3 (ENSG00000142227), CLDND2 (ENSG00000160318), GSG1L (ENSG00000169181), TMEM202 (ENSG00000187806), EMP2 (ENSG00000213853), GSG1L2 (ENSG00000214978)

Protein

Protein identifiers

Lens fiber membrane intrinsic protein — P55344 (reviewed: P55344)

Alternative names: MP18, MP19, MP20

All UniProt accessions (1): P55344

UniProt curated annotations — full annotation on UniProt →

Function. Present in the thicker 16-17 nm junctions of mammalian lens fiber cells, where it may contribute to cell junctional organization. Acts as a receptor for calmodulin. May play an important role in both lens development and cataractogenesis.

Subunit / interactions. Seems to be associated with itself or another lens membrane component via disulfide bonds.

Subcellular location. Membrane.

Tissue specificity. Eye lens specific.

Disease relevance. Cataract, multiple types 19 (CTRCT19) [MIM:615277] An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the PMP-22/EMP/MP20 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P55344-1	1	yes
P55344-2	2, MP19ins

RefSeq proteins (2): NP_001155220, NP_085915 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003935	LMIP	Family
IPR004031	PMP22/EMP/MP20/Claudin	Family
IPR004032	PMP22_EMP_MP20	Family
IPR050579	PMP-22/EMP/MP20-like	Family

Pfam: PF00822

UniProt features (19 total): topological domain 5, transmembrane region 4, glycosylation site 3, modified residue 2, sequence conflict 2, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9CBV	ELECTRON CRYSTALLOGRAPHY	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P55344-F1	90.11	0.67

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 170, 171

Glycosylation sites (3): 43, 61, 62

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 58 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_UP, DARWICHE_PAPILLOMA_PROGRESSION_RISK, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_CELL_JUNCTION_ASSEMBLY, GOBP_SENSORY_ORGAN_DEVELOPMENT, GOBP_CELL_CELL_JUNCTION_ASSEMBLY, SOX5_01, MODULE_207, GOBP_LENS_DEVELOPMENT_IN_CAMERA_TYPE_EYE, CP2_01, GOMF_STRUCTURAL_CONSTITUENT_OF_EYE_LENS, GOMF_STRUCTURAL_MOLECULE_ACTIVITY, GOBP_CELL_CELL_JUNCTION_ORGANIZATION, GOBP_SENSORY_SYSTEM_DEVELOPMENT, WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D

GO Biological Process (3): lens development in camera-type eye (GO:0002088), cell-cell junction assembly (GO:0007043), camera-type eye development (GO:0043010)

GO Molecular Function (1): structural constituent of eye lens (GO:0005212)

GO Cellular Component (4): plasma membrane (GO:0005886), cell junction (GO:0030054), vesicle (GO:0031982), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
camera-type eye development	1
anatomical structure development	1
cell junction assembly	1
cell-cell junction organization	1
eye development	1
structural molecule activity	1
membrane	1
cell periphery	1
membrane-bounded organelle	1

Protein interactions and networks

STRING

1589 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LIM2	TMEM114	B3SHH9	937
LIM2	MIP	P30301	868
LIM2	GJA8	P48165	860
LIM2	CRYAA	P02489	854
LIM2	GJA3	Q9Y6H8	793
LIM2	TAGLN3	Q9UI15	768
LIM2	LHX3	Q9UBR4	765
LIM2	BFSP1	Q12934	728
LIM2	CRYBB3	P26998	727
LIM2	EMP3	P54852	721
LIM2	HSF4	Q9ULV5	721
LIM2	BFSP2	Q13515	719
LIM2	CRYBB1	P53674	708
LIM2	EMP2	P54851	703
LIM2	CRYBA1	P05813	693

IntAct

2 interactions, top by confidence:

A	B	Type	Score
LIM2	ACTA2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (2): ACTA2 (Affinity Capture-MS), ACTA2 (Affinity Capture-MS)

ESM2 similar proteins: A0A8M2B5N2, A0A8V0ZLT4, A1L157, F7BWT7, O35566, O60636, O60637, O75841, O95858, P11049, P20274, P21926, P30413, P30932, P31053, P38573, P40239, P40240, P40241, P48509, P54825, P55344, P56563, P61170, P61171, Q1JQA4, Q2KHY8, Q3SZR9, Q3ZBH3, Q566D0, Q58CY8, Q5RE11, Q61470, Q6GQF5, Q6GR34, Q6IP19, Q6PBE5, Q6PFT6, Q7SZ07, Q80WR1

Diamond homologs: F1QIK8, P20274, P54825, P55344, P56563, Q8NHS1, Q99PA5, Q9D9H2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

113 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	77
Likely benign	14
Benign	10

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
14356	NM_001161748.2(LIM2):c.313T>G (p.Phe105Val)	Pathogenic
224327	NM_001161748.2(LIM2):c.461G>A (p.Gly154Glu)	Pathogenic

SpliceAI

661 predictions. Top by Δscore:

Variant	Effect	Δscore
19:51382066:T:TA	donor_gain	1.0000
19:51380260:TCC:T	acceptor_gain	0.9900
19:51380261:CCC:C	acceptor_gain	0.9900
19:51380501:GTA:G	donor_loss	0.9900
19:51380502:TA:T	donor_loss	0.9900
19:51380504:C:T	donor_loss	0.9900
19:51380527:TGC:T	donor_gain	0.9900
19:51380635:AAGGG:A	acceptor_gain	0.9900
19:51380636:AGGG:A	acceptor_gain	0.9900
19:51380637:GGG:G	acceptor_gain	0.9900
19:51380638:GG:G	acceptor_gain	0.9900
19:51380638:GGCTG:G	acceptor_loss	0.9900
19:51380639:GCTG:G	acceptor_loss	0.9900
19:51380640:C:CC	acceptor_gain	0.9900
19:51380640:C:T	acceptor_loss	0.9900
19:51380641:T:A	acceptor_loss	0.9900
19:51382520:C:CT	acceptor_gain	0.9900
19:51382522:C:CT	acceptor_gain	0.9900
19:51382566:TG:T	acceptor_gain	0.9900
19:51382568:C:CC	acceptor_gain	0.9900
19:51387261:GGGCT:G	donor_loss	0.9900
19:51387262:GGCTC:G	donor_loss	0.9900
19:51387263:GCTCA:G	donor_loss	0.9900
19:51387264:CT:C	donor_loss	0.9900
19:51387265:TCA:T	donor_loss	0.9900
19:51387266:CA:C	donor_loss	0.9900
19:51387267:A:AC	donor_gain	0.9900
19:51387267:ACCG:A	donor_loss	0.9900
19:51387268:C:CC	donor_gain	0.9900
19:51387268:C:CG	donor_loss	0.9900

AlphaMissense

1124 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:51387315:C:A	W43C	0.996
19:51387315:C:G	W43C	0.996
19:51387360:C:A	W28C	0.995
19:51387360:C:G	W28C	0.995
19:51387317:A:G	W43R	0.994
19:51387317:A:T	W43R	0.994
19:51387362:A:G	W28R	0.994
19:51387362:A:T	W28R	0.994
19:51380535:A:G	W144R	0.993
19:51380535:A:T	W144R	0.993
19:51387323:C:G	G41R	0.993
19:51380557:A:C	F136L	0.992
19:51380557:A:T	F136L	0.992
19:51380559:A:G	F136L	0.992
19:51387323:C:A	G41C	0.992
19:51380558:A:G	F136S	0.991
19:51380505:C:G	G154R	0.987
19:51380505:C:T	G154R	0.987
19:51382511:C:G	G78R	0.987
19:51387292:C:G	C51S	0.987
19:51387293:A:T	C51S	0.987
19:51380558:A:C	F136C	0.986
19:51387306:G:C	C46W	0.986
19:51387370:G:A	T25I	0.986
19:51380553:A:G	W138R	0.985
19:51380553:A:T	W138R	0.985
19:51380563:C:A	W134C	0.985
19:51380563:C:G	W134C	0.985
19:51387293:A:G	C51R	0.985
19:51387307:C:G	C46S	0.985

dbSNP variants (sampled 300 via entrez): RS1000110447 (19:51389792 C>T), RS1000111772 (19:51387676 G>A), RS1000156662 (19:51379590 C>G,T), RS1000567037 (19:51386271 T>TCA), RS1001460063 (19:51382728 T>A,G), RS1001810649 (19:51381926 C>T), RS1002176639 (19:51383695 A>C), RS1002459660 (19:51384039 A>G), RS1002586608 (19:51388223 C>A,T), RS1002759535 (19:51383301 C>T), RS1002969304 (19:51379992 G>T), RS1003176902 (19:51385175 G>A), RS1003408928 (19:51379518 T>A,C), RS1003457142 (19:51385363 A>C), RS1003969852 (19:51384264 C>T)

Disease associations

OMIM: gene MIM:154045 | disease phenotypes: MIM:615277, MIM:116200

GenCC curated gene-disease

Disease	Classification	Inheritance
cataract 19 multiple types	Definitive	Autosomal recessive
total early-onset cataract	Supportive	Autosomal dominant

Mondo (3): cataract 19 multiple types (MONDO:0014111), cataract (MONDO:0005129), total early-onset cataract (MONDO:0021548)

Orphanet (1): Early onset non-syndromic cataract (Orphanet:91492)

HPO phenotypes

4 total (5 of 4 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000639	Nystagmus
HP:0000646	Amblyopia
HP:0007780	Cortical pulverulent cataract
HP:0000518	Cataract

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002389_411	Lymphocyte percentage of white cells	2.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007993	lymphocyte percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002386	Cataract	C11.510.245

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases methylation	6
Benzo(a)pyrene	increases expression, affects methylation, decreases methylation	5
trichostatin A	affects cotreatment, decreases expression	3
entinostat	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tetrachlorodibenzodioxin	increases expression	2
GSK-J4	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
mercuric bromide	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
clothianidin	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Vorinostat	decreases expression, affects cotreatment	1
Panobinostat	decreases expression, affects cotreatment	1
Quercetin	increases expression	1
Tobacco Smoke Pollution	increases methylation	1

Clinical trials (associated diseases)

301 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00273221	PHASE4	UNKNOWN	Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial
NCT00312299	PHASE4	COMPLETED	Posterior Capsule Opacification Study
NCT00345046	PHASE4	COMPLETED	A Comparison of Three Different Formulations of Prednisolone Acetate 1%
NCT00347243	PHASE4	COMPLETED	Wavefront Analisys and Contrast Sensitivity of Spherical and Aspherical Intraocular Lenses
NCT00347503	PHASE4	COMPLETED	Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients
NCT00348244	PHASE4	COMPLETED	Ketorolac vs. Steroid in the Prevention of CME
NCT00348270	PHASE4	COMPLETED	Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 and Alcon Laboratories MA60 Acrysof Posterior Chamber Intraocular Lenses
NCT00348582	PHASE4	COMPLETED	Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery
NCT00348621	PHASE4	COMPLETED	A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents
NCT00349583	PHASE4	COMPLETED	Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation
NCT00355446	PHASE4	COMPLETED	Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.
NCT00386438	PHASE4	COMPLETED	Efficacy of Honan Balloon in Intraocular Pressure Reduction Before Phacoemulsification
NCT00392275	PHASE4	COMPLETED	Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs
NCT00428363	PHASE4	COMPLETED	Effect of Optic Edge Design in a Silicone Intraocular Lens on Posterior Capsule Opacification
NCT00449267	PHASE4	COMPLETED	Aurolab Hydrophobic Foldable Intraocular Lens Study
NCT00459303	PHASE4	COMPLETED	Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof
NCT00469690	PHASE4	COMPLETED	Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects
NCT00576485	PHASE4	COMPLETED	Spherical Aberration and Contrast Sensitivity in IOLs
NCT00612729	PHASE4	COMPLETED	Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.
NCT00612781	PHASE4	COMPLETED	Yellow Versus White Study
NCT00630019	PHASE4	COMPLETED	Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
NCT00673803	PHASE4	COMPLETED	Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification
NCT00684138	PHASE4	COMPLETED	ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)
NCT00698724	PHASE4	COMPLETED	Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care
NCT00710905	PHASE4	TERMINATED	Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3
NCT00710931	PHASE4	COMPLETED	Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1
NCT00711347	PHASE4	COMPLETED	Intraoperative Floppy Iris Syndrome
NCT00712244	PHASE4	COMPLETED	DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00719732	PHASE4	COMPLETED	Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3
NCT00721253	PHASE4	COMPLETED	Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA
NCT00731640	PHASE4	COMPLETED	Contralateral ReSTOR / Monofocal or Phakic Eye
NCT00732030	PHASE4	COMPLETED	Low Cylinder Toric
NCT00758199	PHASE4	COMPLETED	Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
NCT00760058	PHASE4	WITHDRAWN	Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL
NCT00760487	PHASE4	COMPLETED	Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens
NCT00761488	PHASE4	WITHDRAWN	Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® Toric
NCT00763360	PHASE4	COMPLETED	To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.
NCT00786370	PHASE4	COMPLETED	Dexmedetomidine vs. Propofol for Cataract Surgery
NCT00786565	PHASE4	COMPLETED	Clinical Evaluation of a New Aspheric Intraocular Lens.